An increased Bax/Bcl‐2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients
Open Access
- 1 August 2018
- journal article
- research article
- Published by Wiley in United European Gastroenterology Journal
- Vol. 6 (7) , 1074-1081
Abstract
Background: Predicting the response of inflammatory bowel disease (IBD) patients to infliximab (IFX) is an unmet clinical need. The expression and density of transmembrane tumor necrosis factor‐α in circulating leukocytes maybe directly related to response by promoting apoptosis.Aim: We tested the hypothesis that direct apoptosis assessment by real‐time polymerase chain reaction evaluation of pro‐apoptotic (Bax) and anti‐apoptotic (Bcl‐2) proteins in peripheral blood mononuclear cells (PBMCs) might be associated with response to IFX.Methods: IFX naïve patients (Crohn's disease, 32 and ulcerative colitis, 20; 35 responders and 17 non‐responders) were evaluated for Bax and Bcl‐2 mRNA expression levels before and 2 weeks after the first infusion. In a subset of patients, apoptosis was also evaluated using flow cytometry.Results: After the first infusion, Bax increased more in responders than in non‐responders (0.7± 0.38 vs 0.81 ± 0.32 and 0.86 ± 0.37 vs 0.87 ± 0.45, respectively, p = 0.071). Bcl‐2 decreased more in responders than in non‐responders (0.71 ± 0.12 vs 0.63 ± 0.13 and 0.81 ± 0.28 vs 0.77 ± 0.27, respectively, p = 0.038). The Bax/Bcl‐2 ratio increased more in responders than in non‐responders (0.99 ± 0.5 vs 1.3 ± 0.51 and 1.03 ± 0.17 vs 1.1 ± 0.28, respectively, p = 0.005). The Bax/Bcl‐2 ratio was able to predict response in 33/52 patients and was correlated to flow cytometry‐assessed apoptosis (r = 0.911; p < 0.001).Conclusions: An increased Bax/Bcl‐2 ratio in PBMCs was associated with therapeutic response to IFX in IBD patients.Keywords
This publication has 39 references indexed in Scilit:
- Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapyAlimentary Pharmacology & Therapeutics, 2011
- The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel DiseaseGastroenterology, 2011
- Review article: loss of response to anti-TNF treatments in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Review: Predicting response to anti-TNF agents for the treatment of Crohn's diseaseTherapeutic Advances in Gastroenterology, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn’s diseaseGut, 2006
- Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implicationsGut, 2006
- Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn’s disease and ulcerative colitisGut, 2004
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993